Product label
Approved product label
People meeting the labeled obesity/overweight and related indication criteria; evidence is product and indication specific.
Reported findings. In a 68-week randomized trial of 1,961 adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes, estimated average weight loss was 14.9% with weekly subcutaneous Wegovy assigned to 2.4 mg, versus 2.4% with placebo. Doses increased over 16 weeks; both groups received diet and physical-activity support. These are study results, not dosing advice.
Nonresponse. At least 5% weight loss was reached by 83.5% with Wegovy versus 31.1% with placebo. Some participants did not reach that threshold; group averages do not predict an individual result.
Harms. Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.
Limits. Labeled preparation only; marketed variants do not inherit approval. This intention-to-treat analysis included all randomized participants and estimated missing week-68 weights from participants in the same assigned group. These injection results do not establish outcomes for oral, compounded or research preparations, or food-noise and personal quality-of-life benefits.
Preparation: Wegovy; other approved semaglutide products have different indications. Route: subcutaneous injection
Read original source ↗Editorial review 2026-10-13. Clinician review pending.